[go: up one dir, main page]

MXPA03001431A - Polimeros de un analogo de epotilona. - Google Patents

Polimeros de un analogo de epotilona.

Info

Publication number
MXPA03001431A
MXPA03001431A MXPA03001431A MXPA03001431A MXPA03001431A MX PA03001431 A MXPA03001431 A MX PA03001431A MX PA03001431 A MXPA03001431 A MX PA03001431A MX PA03001431 A MXPA03001431 A MX PA03001431A MX PA03001431 A MXPA03001431 A MX PA03001431A
Authority
MX
Mexico
Prior art keywords
polymorphs
epothilone analog
epothilone
mixtures
formula
Prior art date
Application number
MXPA03001431A
Other languages
English (en)
Inventor
Zhenrong Guo
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22845469&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA03001431(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MXPA03001431A publication Critical patent/MXPA03001431A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proporciona de acuerdo con la presente invencion dos polimorfos cristalinos, designados forma A y forma B, respectivamente, asi como mezclas de loa mismos, de un analogo de epotilona representado par la formula (I); (Ver formula).Tambien se proporcionan metodos para formar los polimorfos novedosos, metodos terapeuticos que los utilizan y forma de dosificacion farmaceuticas que los contienen.
MXPA03001431A 2000-08-16 2001-08-01 Polimeros de un analogo de epotilona. MXPA03001431A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22559000P 2000-08-16 2000-08-16
PCT/US2001/024540 WO2002014323A2 (en) 2000-08-16 2001-08-01 Polymorphs of an epothilone analog

Publications (1)

Publication Number Publication Date
MXPA03001431A true MXPA03001431A (es) 2004-05-04

Family

ID=22845469

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03001431A MXPA03001431A (es) 2000-08-16 2001-08-01 Polimeros de un analogo de epotilona.

Country Status (41)

Country Link
US (4) US6689802B2 (es)
EP (1) EP1309597B1 (es)
JP (1) JP5046467B2 (es)
KR (1) KR100810342B1 (es)
CN (1) CN1269821C (es)
AR (1) AR034259A1 (es)
AT (1) ATE366735T1 (es)
AU (2) AU8108201A (es)
BG (1) BG66132B1 (es)
BR (1) BR0113234A (es)
CA (1) CA2418109C (es)
CY (1) CY1107758T1 (es)
CZ (1) CZ305523B6 (es)
DE (1) DE60129334T2 (es)
DK (1) DK1309597T3 (es)
EE (1) EE05273B1 (es)
ES (1) ES2288518T3 (es)
GE (1) GEP20053495B (es)
HR (1) HRP20030190B1 (es)
HU (1) HU229314B1 (es)
IL (2) IL153993A0 (es)
IS (1) IS2845B (es)
LT (1) LT5138B (es)
LV (1) LV13032B (es)
MX (1) MXPA03001431A (es)
MY (1) MY134129A (es)
NO (1) NO328500B1 (es)
NZ (1) NZ523722A (es)
PE (1) PE20020290A1 (es)
PL (1) PL205628B1 (es)
PT (1) PT1309597E (es)
RO (1) RO123296B1 (es)
RU (1) RU2272039C2 (es)
SI (1) SI21100B (es)
SK (1) SK287876B6 (es)
TW (1) TWI320040B (es)
UA (1) UA75365C2 (es)
UY (1) UY26886A1 (es)
WO (1) WO2002014323A2 (es)
YU (1) YU12103A (es)
ZA (1) ZA200300522B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0977563B1 (en) 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
IL156578A0 (en) * 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for pharmaceutical use and pharmaceutical preparations including an epothilone analog
RU2003126171A (ru) * 2001-01-25 2005-02-27 Бристол-Маерс Сквибб Компани (Us) Парентеральный состав, содержащий аналоги эпотилона
EE200300396A (et) 2001-02-20 2003-12-15 Bristol-Myers Squibb Company Epotilooni derivaatide kasutamine refraktaarsete kasvajate raviks
WO2002072085A1 (en) * 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
PT1485090E (pt) * 2002-03-08 2008-01-14 Novartis Ag Combinações compreendendo um derivado de epotilona e uma imidazotetrazinona
WO2004018478A2 (en) * 2002-08-23 2004-03-04 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
BRPI0518286A2 (pt) * 2004-11-18 2008-11-11 Bristol Myers Squibb Co microesfera com revestimento entÉrico contendo ixabepilona e sua preparaÇço
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
EP1856255A4 (en) 2005-02-11 2010-01-27 Univ Southern California PROCESS FOR EXPRESSING PROTEINS VIA DISULPHIDE BRIDGES
DK1698630T3 (da) 2005-03-03 2014-12-08 Alfa Wassermann Spa Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater
US7772177B2 (en) 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
US7693596B2 (en) 2005-12-14 2010-04-06 Dell Products L.P. System and method for configuring information handling system integrated circuits
US20080286325A1 (en) * 2006-01-05 2008-11-20 Med Institute, Inc. Cyclodextrin elution media for medical device coatings comprising a taxane therapeutic agent
US7919108B2 (en) * 2006-03-10 2011-04-05 Cook Incorporated Taxane coatings for implantable medical devices
US7875284B2 (en) * 2006-03-10 2011-01-25 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
US20110104664A1 (en) 2006-03-31 2011-05-05 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to micortubule-stabilizing agents
EP2029156A4 (en) 2006-05-01 2010-07-21 Univ Southern California COMBINATION THERAPY FOR CANCER TREATMENT
AU2007250443B2 (en) 2006-05-16 2013-06-13 Pharmascience Inc. IAP BIR domain binding compounds
WO2008019820A2 (en) * 2006-08-16 2008-02-21 Novartis Ag Crystal form of epothilone b and use in pharmaceutical compositions
US8463852B2 (en) * 2006-10-06 2013-06-11 Oracle International Corporation Groupware portlets for integrating a portal with groupware systems
US20110124690A1 (en) * 2007-02-23 2011-05-26 Danishefsky Samuel J Compositions and methods for treating cancer or a neurotrophic disorder
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2070521A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Surface-modified nanoparticles
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
NZ602368A (en) 2010-02-12 2014-10-31 Pharmascience Inc Iap bir domain binding compounds
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
KR20130086534A (ko) * 2010-06-01 2013-08-02 플러스 케미칼스, 에스.에이. 익사베필론의 고체 형태
EP2793949B1 (en) 2011-12-23 2018-08-22 Innate Pharma Enzymatic conjugation of antibodies
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
EP2872894B1 (en) 2012-07-13 2019-04-17 Innate Pharma Screening of conjugated antibodies
EP2916872B1 (en) 2012-11-09 2019-02-27 Innate Pharma Recognition tags for tgase-mediated conjugation
CN103183681B (zh) * 2013-03-06 2016-01-13 浙江海正药业股份有限公司 伊沙匹隆的新晶型及其制备方法
EP2968582B1 (en) 2013-03-15 2020-07-01 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
WO2014202773A1 (en) 2013-06-20 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
CA2914189C (en) 2013-06-21 2023-03-14 Innate Pharma Enzymatic conjugation of polypeptides
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues
EP4097245A1 (en) 2020-01-31 2022-12-07 Allarity Therapeutics Europe ApS Methods for predicting ixabepilone responsiveness in cancer patients
CN112409366A (zh) * 2020-11-30 2021-02-26 湖北宏中药业股份有限公司 一种伊沙匹隆二聚体的高收率制备方法
CN112457320A (zh) * 2020-11-30 2021-03-09 湖北宏中药业股份有限公司 一种提高伊沙匹隆合成反应速率的方法
CN112375085A (zh) * 2020-11-30 2021-02-19 湖北宏中药业股份有限公司 一种伊沙匹隆反应液的高收率高纯度处理方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1000809A (en) * 1960-11-02 1965-08-11 James Oakes & Company Riddings Pipe manufacture
DE2308418B2 (de) * 1972-06-21 1976-04-08 Petzetakis, Aristovoulos George, Moschaton, Piräus (Griechenland) Verfahren und vorrichtung zum herstellen eines insbesondere grosskalibrigen rohres aus thermoplastischem kunststoff
JPS5240337B2 (es) * 1973-01-29 1977-10-12
SE386365B (sv) * 1973-07-25 1976-08-09 L Brendling Behallare av plast, gummi eller annat bojligt material, spec. avsedd for uppsamling av urin och/eller fekalier
JPS6398413A (ja) * 1986-10-15 1988-04-28 Smc Corp 二重管およびその連続製造法
DE3927569A1 (de) * 1989-08-21 1991-02-28 Fritz Egger Gmbh Elektroabscheider zum abscheiden von schwebstoffen aus gasen
DE3939714A1 (de) * 1989-12-01 1991-06-06 Baedje K H Meteor Gummiwerke Schlauch
AU6431790A (en) * 1990-01-05 1991-08-05 Orscheln Co. Flexible synthetic plastic conduit
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE4206096A1 (de) * 1992-02-27 1993-09-02 Wolf Woco & Co Franz J Koaxialrohr
EP1440973A3 (de) 1995-11-17 2004-10-20 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilonderivate, Herstellung und Mittel
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
WO1998008849A1 (de) 1996-08-30 1998-03-05 Novartis Aktiengesellschaft Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
PL193229B1 (pl) 1996-11-18 2007-01-31 F Biotechnologische Forschung Epotylon C, epotylon D, epotylon E i epotylon F, sposób biotransformacji epotylonu A, sposób biotransformacji epotylonu B oraz środek leczniczy
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
EP0977563B1 (en) 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
WO1998038192A1 (de) * 1997-02-25 1998-09-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Seitenkettenmodifizierte epothilone
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
EP0975622B1 (de) 1997-04-18 2002-10-09 Studiengesellschaft Kohle mbH Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
ES2184307T3 (es) 1997-07-16 2003-04-01 Schering Ag Derivados de tiazol, procedimiento para su preparacion y su utilizacion.
JP2001512723A (ja) 1997-08-09 2001-08-28 シエーリング アクチエンゲゼルシヤフト 新規エポチロン誘導体、その製法およびその薬学的使用
DE19747580A1 (de) 1997-10-28 1999-04-29 Siemens Ag Rangierfeld mit Anschlußleiste
US6365749B1 (en) * 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
HUP0101564A3 (en) 1998-02-05 2002-06-28 Novartis Ag Compositions containing epothilone
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
DE19807505A1 (de) 1998-02-21 1999-08-26 Roland Man Druckmasch Bogenrotationsdruckmaschine mit Druckeinheiten für den Mehrfarbendruck und wenigstens einer Beschichtungseinheit
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
MXPA00008365A (es) 1998-02-25 2002-11-07 Sloan Kettering Inst Cancer Sintesis de epotilonas, intermediarios y analogos de las mismas.
WO2000000485A1 (de) 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
AU5325699A (en) * 1998-08-12 2000-03-06 Proteus Inc. Ribbed core dual wall structure
AU2795000A (en) 1998-12-22 2000-07-12 Novartis Ag Epothilone derivatives and their use as antitumor agents
RU2242229C2 (ru) * 1999-01-19 2004-12-20 Новартис Аг Применение эпотилонов для лечения рака
AR023792A1 (es) 1999-04-30 2002-09-04 Bayer Schering Pharma Ag Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
US6605559B1 (en) 1999-09-29 2003-08-12 Daihatsu Motor Co., Ltd. Dimethyl ether reforming catalyst
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
EE05301B1 (et) 2001-01-25 2010-06-15 Bristol-Myers Squibb Company Meetod epotilooni analooge sisaldavate ravimvormide valmistamiseks ning nende kasutamine ravimi valmistamiseks
RU2003126171A (ru) 2001-01-25 2005-02-27 Бристол-Маерс Сквибб Компани (Us) Парентеральный состав, содержащий аналоги эпотилона
US9317043B2 (en) 2013-12-19 2016-04-19 Google Inc. Path based power generation control for an aerial vehicle

Also Published As

Publication number Publication date
AR034259A1 (es) 2004-02-18
EE200300063A (et) 2004-12-15
AU8108201A (en) 2002-02-25
BG66132B1 (bg) 2011-06-30
SK287876B6 (sk) 2012-02-03
EP1309597A2 (en) 2003-05-14
NO20030707D0 (no) 2003-02-14
US7153879B2 (en) 2006-12-26
DE60129334T2 (de) 2008-04-03
WO2002014323A3 (en) 2002-05-02
LT2003017A (en) 2004-03-25
ATE366735T1 (de) 2007-08-15
RO123296B1 (ro) 2011-06-30
US6689802B2 (en) 2004-02-10
US20040157897A1 (en) 2004-08-12
SI21100B (sl) 2009-12-31
CN1269821C (zh) 2006-08-16
BR0113234A (pt) 2004-02-25
KR100810342B1 (ko) 2008-03-07
PL205628B1 (pl) 2010-05-31
EP1309597B1 (en) 2007-07-11
HU229314B1 (en) 2013-10-28
CA2418109A1 (en) 2002-02-21
CA2418109C (en) 2011-09-27
AU2001281082B2 (en) 2007-01-04
PL365610A1 (en) 2005-01-10
ZA200300522B (en) 2004-04-20
HUP0300826A2 (hu) 2003-09-29
WO2002014323A2 (en) 2002-02-21
CZ2003418A3 (cs) 2004-01-14
KR20030022411A (ko) 2003-03-15
LT5138B (lt) 2004-06-25
UY26886A1 (es) 2002-03-22
SK1342003A3 (en) 2003-09-11
LV13032B (en) 2003-12-20
CN1468243A (zh) 2004-01-14
HRP20030190B1 (en) 2011-07-31
CZ305523B6 (cs) 2015-11-18
US20020188014A1 (en) 2002-12-12
NO20030707L (no) 2003-04-15
HK1052010A1 (en) 2003-08-29
HUP0300826A3 (en) 2005-05-30
BG107467A (bg) 2003-09-30
TWI320040B (en) 2010-02-01
JP2004506638A (ja) 2004-03-04
EE05273B1 (et) 2010-02-15
US6982276B2 (en) 2006-01-03
US20060063815A1 (en) 2006-03-23
GEP20053495B (en) 2005-04-25
DE60129334D1 (en) 2007-08-23
JP5046467B2 (ja) 2012-10-10
PT1309597E (pt) 2007-08-22
IS6714A (is) 2003-02-11
UA75365C2 (en) 2006-04-17
ES2288518T3 (es) 2008-01-16
NZ523722A (en) 2005-04-29
USRE39251E1 (en) 2006-08-29
IL153993A0 (en) 2003-07-31
PE20020290A1 (es) 2002-04-03
IL153993A (en) 2009-07-20
HRP20030190A2 (en) 2003-04-30
NO328500B1 (no) 2010-03-01
MY134129A (en) 2007-11-30
CY1107758T1 (el) 2013-06-19
RU2272039C2 (ru) 2006-03-20
YU12103A (sh) 2006-08-17
SI21100A (sl) 2003-06-30
DK1309597T3 (da) 2007-10-22
IS2845B (is) 2013-08-15

Similar Documents

Publication Publication Date Title
YU12103A (sh) Polimorfni oblici epotilonskog analoga
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
MXPA02007942A (es) Derivados de pirrolopirimidinona, procesos de preparacion y uso.
SE0001899D0 (sv) New compounds
GB0003154D0 (en) Novel compounds
AU7775401A (en) Proline derivatives and use thereof as drugs
SE9904505D0 (sv) Novel compounds
AP2002002637A0 (en) Novel piperazine
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
TR200200785T2 (tr) 8-Fenil-6,9-dihidro-[1,2,4] triazolo [3,4-i] purin-5-on türevleri
WO2004055006A8 (en) Novel compounds having selective inhibiting effect at gsk3
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
IL176062A0 (en) Dpp-iv inhibitors
WO2006005609A3 (de) Substituierte oxindol-derivate und diese enthaltende arzneimittel
PL364598A1 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
SE0302192D0 (sv) Novel compounds
GB0109122D0 (en) Novel compounds
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
MXPA02009643A (es) Sintesis acortada de derivados de 3,3-diarilpropilamina.
PL1758852T3 (pl) Podstawione związki cyklopentenu
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
MXPA04004090A (es) Compuestos substituidos de 1h-quinolin-2-ona.
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
NZ527230A (en) Crystal form of a cyclic depsipeptide having improved activity
YU70502A (sh) Amorfna modifikacija torasemida

Legal Events

Date Code Title Description
FG Grant or registration